MA31534B1 - Particules d'antagoniste de crth2 - Google Patents

Particules d'antagoniste de crth2

Info

Publication number
MA31534B1
MA31534B1 MA32538A MA32538A MA31534B1 MA 31534 B1 MA31534 B1 MA 31534B1 MA 32538 A MA32538 A MA 32538A MA 32538 A MA32538 A MA 32538A MA 31534 B1 MA31534 B1 MA 31534B1
Authority
MA
Morocco
Prior art keywords
crth2 antagonist
antagonist particles
methods
particles
crth2
Prior art date
Application number
MA32538A
Other languages
English (en)
Inventor
Tai Wei Ly
Hui-Yin Li
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31534(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of MA31534B1 publication Critical patent/MA31534B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR DES PARTICULES D'ACIDE {4,6-BIS(DIMÉTHYLAMINO)-2-(4-(4-(TRIFLUOROMÉTHYL)BENZAMIDO)BENZYL)PYRIMIDIN-5-YL} ACÉTIQUE DANS DES FORMES AMORPHES OU CRISTALLINES, SUR DES PROCÉDÉS PERMETTANT DE LES PRÉPARER, SUR DES COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT, ET SUR DES PROCÉDÉS POUR LES UTILISER POUR LE TRAITEMENT, LA PRÉVENTION OU L'AMÉLIORATION D'UN OU PLUSIEURS SYMPTÔMES D'UN TROUBLE OU D'UNE MALADIE À MÉDIATION PAR CRTH2.
MA32538A 2007-06-21 2010-01-19 Particules d'antagoniste de crth2 MA31534B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93697207P 2007-06-21 2007-06-21

Publications (1)

Publication Number Publication Date
MA31534B1 true MA31534B1 (fr) 2010-07-01

Family

ID=39708813

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32538A MA31534B1 (fr) 2007-06-21 2010-01-19 Particules d'antagoniste de crth2

Country Status (21)

Country Link
US (1) US8507005B2 (fr)
EP (1) EP2170838A1 (fr)
JP (1) JP2010530425A (fr)
KR (1) KR20100023046A (fr)
CN (3) CN101778830B (fr)
AR (1) AR067119A1 (fr)
AU (1) AU2008266853A1 (fr)
BR (1) BRPI0813436A2 (fr)
CA (1) CA2690172A1 (fr)
CL (1) CL2008001818A1 (fr)
CO (1) CO6290713A2 (fr)
EC (1) ECSP109890A (fr)
HK (1) HK1144939A1 (fr)
IL (1) IL202679A0 (fr)
MA (1) MA31534B1 (fr)
NZ (1) NZ581811A (fr)
RU (1) RU2468012C2 (fr)
TN (1) TN2009000518A1 (fr)
TW (1) TW200911762A (fr)
UA (1) UA99138C2 (fr)
WO (1) WO2008156780A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
US8278310B2 (en) * 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2009108720A2 (fr) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs d2 de la prostaglandine
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (fr) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Antagonistes d’hétéroaryle des récepteurs de la prostaglandine d2
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2011005645A1 (fr) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Polymorphe de [4,6-bis(diméthylamino)-2-(4-{[4-(trifluorométhyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acétique
EP2461809A4 (fr) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
EA201200765A1 (ru) 2009-11-24 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
WO2011066147A2 (fr) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Nouvelles formes salines d'un dérivé de l'acide pyrimidin-5-yl acétique
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EP3638208A1 (fr) * 2017-06-12 2020-04-22 Novartis AG Matériaux pharmaceutiques nanostructurés amorphes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078690B2 (en) * 2002-02-04 2006-07-18 Applied Materials, Israel, Ltd. Monitoring of contact hole production
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
RU2373208C2 (ru) * 2004-01-31 2009-11-20 Актимис Фармасьютикалз, Инк. Производные имидазо[1,2-c]пиримидинилуксусной кислоты

Also Published As

Publication number Publication date
KR20100023046A (ko) 2010-03-03
IL202679A0 (en) 2010-06-30
EP2170838A1 (fr) 2010-04-07
CN103172573A (zh) 2013-06-26
HK1144939A1 (en) 2011-03-18
CL2008001818A1 (es) 2009-03-06
CN101778830B (zh) 2013-03-20
RU2010101804A (ru) 2011-07-27
ECSP109890A (es) 2010-03-31
TW200911762A (en) 2009-03-16
CA2690172A1 (fr) 2008-12-24
WO2008156780A1 (fr) 2008-12-24
AU2008266853A1 (en) 2008-12-24
US20110052701A1 (en) 2011-03-03
US8507005B2 (en) 2013-08-13
CN101778830A (zh) 2010-07-14
UA99138C2 (ru) 2012-07-25
CO6290713A2 (es) 2011-06-20
BRPI0813436A2 (pt) 2014-12-23
RU2468012C2 (ru) 2012-11-27
NZ581811A (en) 2012-11-30
AR067119A1 (es) 2009-09-30
CN103172572A (zh) 2013-06-26
TN2009000518A1 (en) 2011-03-31
JP2010530425A (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
MA31534B1 (fr) Particules d'antagoniste de crth2
MA31536B1 (fr) Sels d'amines d'un antagoniste de crth2
MA31457B1 (fr) N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides
MA33142B1 (fr) Mutants fgf21 et leurs utilisations
TN2010000068A1 (en) Anticorps anti-cd37
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
BRPI0610187B8 (pt) tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo
MA31881B1 (fr) Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
MA38643A1 (fr) Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA33293B1 (fr) Procédé d'amélioration du profil de dissolution d'une matière biologiquement active
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA34120B1 (fr) Composition pharmaceutique
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
NO20075154L (no) Formuleringer av en src/abl-inhibitor
MA31707B1 (fr) Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
Voss et al. THU0127 Pharmacodynamics of a novel JAK1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects
UA96764C2 (ru) Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl
MA30330B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
MA29723B1 (fr) Composes
NO20085270L (no) Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni